NAD + in fatty liver disease: mechanistic insights and associated targets.
Level 5 - mechanism / opinion, no new human data
Narrative review describing biological mechanisms without systematic search methodology or original human trial data.
PubMed 41291376 · doi:10.1007/s10565-025-10106-7
What was done
This narrative review synthesized literature on the mechanistic roles and therapeutic potential of nicotinamide adenine dinucleotide (NAD+) in metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-associated liver disease (ALD).
What was found
The abstract reports no quantitative values or statistical results. It qualitatively states that NAD+ depletion is associated with fatty liver disease and that restoring NAD+ levels mitigates disease progression by influencing lipid accumulation, oxidative stress, endoplasmic reticulum stress, inflammation, autophagy, and fibrosis.
Why it matters
It highlights cellular pathways linking NAD+ metabolism to chronic liver pathology, identifying potential molecular targets for non-alcoholic and alcohol-related liver diseases.
Limits
As a narrative review, it presents no original clinical data or statistical results. It does not employ a systematic review methodology or report sample sizes.
Cited by
- supports Individuals with alcoholism exhibit disturbed NAD metabolism in liver tissue.